Gubra A/S engages in providing research and development services to pharmaceutical and biotechnology companies on a contract basis. It operates through two business segments: Pre-clinical Contract Research (CRO), Discovery and Partnerships (D and P), and Gubra Green. The CRO segment refers to pre-clinical contract research and development services within metabolic and fibrotic diseases. The D and P segment include portfolio strategy in the form of upfront payments, research payments, milestone payments, and royalties. The Gubra Green segment relates to investments in targeting assets. The company was founded by Jacob Jelsing and Niels Vrang in 2008 and is headquartered in Hørsholm, Denmark.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company